18 / 60
HIPERTENSIÓN / 2014 / VOL. 19
16
La Guía termina con un interesante comentario sobre temas relevantes que todavía están en
discusión y que deben ser analizados a través de futuras investigaciones. Se mencionan brechas
a dilucidar a través de 13 preguntas, lo cual sólo demuestra que en HTA no está todo escrito.
Bibliografía
1.
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013;34:2159-2219
2.
James P, Oparil S, Carter B et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report from the panel members
appointed to the Eight Joint National Committe (JNC 8). JAMA. 2014;311(5):507-520
3.
Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered?
A critical reappraisal. J Hypertens 2009; 27: 923-934
4.
Schier RW, Estacio RO, Esler A et al. Effects of agressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and
stroke. Kidney Int 2002; 61:1086-1097.
5.
The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
6.
The Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in MICROHOPE
substudy. Lancet 2000; 355: 253-259
7.
Advance Collaborative Group. Effects of a fixed combination of perindropil and indapamide on macrovascular and microvascular outcomes in patients with
type 2 diabetes mellitus ( the ADVENCE trial ): a randomised controlled trial. Lancet 2007; 370: 829-840
8.
Estacio RO, Jeffers BW, Gifford N et al. Effect of blood pressure control on diabetic microvacular complications in patients with hypertension and type 2
diabetes. Diabetes Care 2000; 23 (Suppl. 2): B54-B64
9.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results
of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762
10.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes; UKPDS
38. Br Med J 1998:317:703-713
11.
JATOS Study Group. Principal results of the Japanese Trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res
2008; 31: 2115-2127
12.
Zhang Y, Zhang X, Liu L, et al. Is a systolic blood pressure target < 140 mmHg indicated in all hypertensives? Subgroup analysis of findings from the randomized
FEVER trial. Eur Heart J 2011; 32:1500-1508
13.
Blood Pressure Lowering Treatment Trialists ´Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and
younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123
14.
Wright J, Bakris G, Greene T et al. Effect of blood pressure lowering and hypertensive drug class on progression of hypertensive kidney disease: results from
de AASK Trial. JAMA 2002; 288:2421-2431
15.
Upadhyay A, Earley A, Haynes SM et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern
Med 2011; 154:541-548
16.
Dahlof B, Devereux R, Kjeldsen et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):
a randomised trial against atenolol. Lancet 2002; 359:995-1003
17.
Law M , Morris J, Wald N. Use of blood-pressure-lowering drugs in the prevention of cardiovascular disease: meta analysis of 147 randomised trials in the
context of expectations from prospective epidemiological studies. BMJ 2009 338, b1665.
18.
Willian B, Lacy P, Thom S, et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the
Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113: 1213-125.